Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer

By afschroeder • April 23, 2026

Fakih M, Gill S, Sampat K, Chan DL, Fisher G, Cruz-Correa M, Lenz HJ, Garcia-Alfonso P, Forget F, Lonardi S, Krauss J, Chen E, Cubillo Gracian A, Liu Y, van Buuren N, Shao J, Dong M, Chen A, Tejani M, Hecht JR. Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer. ESMO Gastrointest Oncol. 2026 Apr 17;12:100324. doi: 10.1016/j.esmogo.2026.100324. PMID: 42022129; PMCID: PMC13098452.

Tags: Bevacizumab, FOLFIRI, Hematology/Oncology, magrolimab, Metastatic colorectal cancer, Publications

Related Posts

Inhibition of Acetyl-CoA-carboxylase induces endoplasmic reticulum stress and augments the efficacy of anti-cancer therapies

Shan NL, Balinda H, Dai J, Wang Y, Lin HK, Marczyk M, Espinoza Campos G, Umlauf S, McDermott MSJ, Colorado I, Lang SM, Surovtseva YV,[...]

Early-Onset Gastric Cancer as a High-Risk Disease Entity in the United States: Clinicopathologic Features, Regional Variation, and Outcomes

Castillo DR, Shah P, Tai D, Guo M, Hazeltine M, Guzman S, Park D, Mannan R, Xing Y, Brar G, Raoof M, Eng C, Wu[...]

Women and Herpes Zoster in the United States: Risk and Prevention Management-A Narrative Review

Campos R, Caldera F, Carrico J, Cochrane C, Eltoukhy N, Huang C, Kneller S, Rutland C, Slovis J. Women and Herpes Zoster in the United[...]